Cytosolix has discovered a way to re-engineer existing chemotherapeutics to target solid tumors

The Problem

Side-effects of chemotherapy

Chemotherapy often causes serious side effects, limiting its ability to treat cancer.  Side effects are a consequence of off-target drug uptake of these toxic agents in healthy tissues.

The Solution

Tumor-targeted drug delivery

While antibody-drug conjugates show the benefits of targeted delivery, antibodies target very rare molecular biomarkers, limiting the benefits of this technology to just a few cancers.  Most patients still rely on untargeted therapies.

The Opportunity

A universal cancer biomarker

Tumor acidity provides a biomarker for targeted drug delivery to 95% of cancers. Acidity is an unavoidable consequence of the way cancers grow and metabolize that is universal to solid tumors.

Value Proposition

A small-molecule tumor-targeted platform

Cytosolix has a unique approach to improve existing therapeutics that is applicable to most classes of small molecule drugs.

Targets drug-delivery to an unexploited, newly-validated biomarker universal to solid tumors - 95% of cancers.

Improved safety and therapeutic index enables more intensive therapy and better outcomes with lower side effects.

Revised Bar Chart Graphic

The Team

Management Team

JohnDeacon-Cytosolix

John C. Deacon, Ph.D.

Founder and President

Associate Research Scientist, Yale School of Medicine

Advisory Team

Colin Foster
Colin Foster, M.B.A.

Business Strategy

Formerly CEO, Bayer North America

 

IMG_3449 (002)
Wayne Klohs, Ph.D.

Oncology Strategy

Formerly Senior VP Global Oncology, Astellas

Formerly Head of Oncology, Pfizer

Terrence W. Doyle, Ph.D.
Terrence Doyle, Ph.D.

R&D Strategy

Formerly Director of Preclinical Cancer Research, BMS

Formerly CSO, Vion Pharmaceuticals

Dr. Joseph Paul Eder
J. Paul Eder, M.D.

Clinical Strategy

Director Phase I Program, Yale Cancer Center

Formerly Medical Science Director, AstraZeneca

 

Stephen B. Sasson, Ph.D.
Stephen Sasson Ph.D.

Regulatory Strategy

Formerly VP World Regulatory Affairs, and Clinical & Medical Sciences Team Leader, Pfizer

 

The Cytosolix Opportunity

1

100-fold
Improvements

Our approach achieves up to 100-fold improvements without changing the active agent

2

Clinical Translation

Preclinical examples show that our core concept translates to therapeutic outcomes

3

Regulatory Advantages

Our platform can bring first-in-class targeted therapies to new indications, addressing unmet clinical needs

4

Numerous Applications

Our platform can be applied to nearly every class of small molecule chemotherapy

 

Targeting tumor acidity can be built into drug discovery in oncology - revolutionizing the next generation of chemotherapy

Cytosolix is positioned to lead the industry into a new era of tumor-targeted drug-delivery

ARE YOU READY TO HELP
Revolutionize Oncology?

© 2018 Cytosolix | website by HalaganDesign.com